Synergistic Inhibition of PI3K and HSP90 Enhanced Antitumorigenic Efficacy in Adrenocortical Carcinoma
RNA-seq (gene expression) · human · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 18 samples: 6 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE330925_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1466199 and SRA study SRP700490. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 18 samples.
How we read this: 6 replicated groups read from 18 sample titles; they account for 18 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9735823 Untreated ACC cells HC1 Untreated ACC cells HC
- GSM9735824 Untreated ACC cells HC2 Untreated ACC cells HC
- GSM9735825 Untreated ACC cells HC3 Untreated ACC cells HC
- GSM9735826 STA9090 treated ACC cells HS1 STA9090 treated ACC cel…
- GSM9735827 STA9090 treated ACC cells HS2 STA9090 treated ACC cel…
- GSM9735828 STA9090 treated ACC cells HS3 STA9090 treated ACC cel…
- GSM9735829 PIK75 treated ACC cells HP1 PIK75 treated ACC cells…
- GSM9735830 PIK75 treated ACC cells HP2 PIK75 treated ACC cells…
- GSM9735831 PIK75 treated ACC cells HP3 PIK75 treated ACC cells…
- GSM9735832 BGT226 treated ACC cells HB1 BGT226 treated ACC cell…
- GSM9735833 BGT226 treated ACC cells HB2 BGT226 treated ACC cell…
- GSM9735834 BGT226 treated ACC cells HB3 BGT226 treated ACC cell…
- GSM9735835 STA9090+PIK75 treated ACC cells HSP1 STA9090+PIK75 treated A…
- GSM9735836 STA9090+PIK75 treated ACC cells HSP2 STA9090+PIK75 treated A…
- GSM9735837 STA9090+PIK75 treated ACC cells HSP3 STA9090+PIK75 treated A…
- GSM9735838 STA9090+BGT226 treated ACC cells HSB1 STA9090+BGT226 treated …
- GSM9735839 STA9090+BGT226 treated ACC cells HSB2 STA9090+BGT226 treated …
- GSM9735840 STA9090+BGT226 treated ACC cells HSB3 STA9090+BGT226 treated …
- GSE310085 Sulforaphane Inhibits Colorectal Cancer Progression via PI3K/AKT/mTOR and HIF-1α Suppression with Enhanced Efficacy under Hypoxia 9 samples shares pi3k, enhanced, efficacy
- GSE271516 Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in Diffuse large B-cell lymphoma 6 samples shares pi3k, synergistic, efficacy
- GSE237512 PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification 39 samples shares pi3k, inhibition
- GSE279738 A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcoma. 32 samples shares pi3k, synergistic
- GSE312764 VEGF/ERK activation and PI3K inhibition together drive a vein-to-artery transition in an in vitro model of human angiogenesis 21 samples shares pi3k, inhibition
- GSE243654 Targeting PI3Kgamma dependency in leukemia treatment [PI3Kgamma inhibition] 18 samples shares pi3k, inhibition
- GSE221833 Next Generation Sequencing Analysis of Breast Cancer Cell Line MCF-7 And MDA-MB-231 After PI3K Inhibition 12 samples shares pi3k, inhibition
- GSE278506 Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with enhanced PI3K/AKT/mTOR signal signature 12 samples shares pi3k, enhanced
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.